Payment overview · 2025
General Payments
$105.58
4 reported records · 4 companies
Healthcare provider profile · identity verified
Sharon Mitchell, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · LIBERAL, KS · NPI 1417145913
Verified facts
What the public records show
CMS Open Payments records show Sharon Mitchell, M.D. received $105.58 in general payments during 2025 across 4 reported records.
Medtronic, Inc. accounted for 32.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$34.58 | 32.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $34.35 | 32.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.22 | 19.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.43 | 15.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $85.36 | 3 |
| Education | $20.22 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $34.58 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $34.35 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.22 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
140 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 276 | 74 |
| Levothyroxine Sodium | Levothyroxine Sodium | 200 | 38 |
| Farxiga | Dapagliflozin Propanediol | 140 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 140 | 39 |
| Amlodipine Besylate | Amlodipine Besylate | 138 | 36 |
| Omeprazole | Omeprazole | 129 | 35 |
| Potassium Chloride | Potassium Chloride | 119 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 116 | 30 |
| Metformin Hcl | Metformin Hcl | 102 | 31 |
| Gabapentin | Gabapentin | 94 | 29 |
| Telmisartan | Telmisartan | 93 | 21 |
| Ozempic | Semaglutide | 78 | 11 |
| Metoprolol Succinate | Metoprolol Succinate | 73 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 73 | suppressed |
| Azithromycin | Azithromycin | 71 | 38 |
| Famotidine | Famotidine | 71 | 18 |
| Furosemide | Furosemide | 69 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 66 | 11 |
| Acarbose | Acarbose | 61 | 12 |
| Allopurinol | Allopurinol | 61 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 57 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 56 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 54 | 11 |
| Lisinopril | Lisinopril | 53 | 18 |
| Estradiol | Estradiol | 50 | 18 |
| Tramadol Hcl | Tramadol Hcl | 48 | 11 |
| Sucralfate | Sucralfate | 45 | 11 |
| Entresto | Sacubitril/Valsartan | 44 | suppressed |
| Carvedilol | Carvedilol | 42 | 15 |
| Pregabalin | Pregabalin | 42 | 14 |
| Montelukast Sodium | Montelukast Sodium | 40 | 11 |
| Irbesartan | Irbesartan | 39 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 39 | 14 |
| Eliquis | Apixaban | 38 | suppressed |
| Nifedipine Er | Nifedipine | 38 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 37 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 37 | 12 |
| Losartan Potassium | Losartan Potassium | 37 | 15 |
| Lansoprazole | Lansoprazole | 35 | suppressed |
| Jardiance | Empagliflozin | 34 | suppressed |
| Torsemide | Torsemide | 34 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | 11 |
| Colchicine | Colchicine | 31 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 31 | suppressed |
| Spironolactone | Spironolactone | 31 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Valsartan | Valsartan | 29 | suppressed |
| Alprazolam | Alprazolam | 28 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 28 | suppressed |
| Meloxicam | Meloxicam | 28 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 28 | suppressed |
| Bumetanide | Bumetanide | 27 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 26 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 15 |
| Cefuroxime | Cefuroxime Axetil | 26 | 22 |
| Celecoxib | Celecoxib | 26 | suppressed |
| Prednisone | Prednisone | 26 | 15 |
| Topiramate | Topiramate | 25 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | 19 |
| Levofloxacin | Levofloxacin | 23 | 13 |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 23 | suppressed |
| Simvastatin | Simvastatin | 23 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 16 |
| Nitroglycerin Patch | Nitroglycerin | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 14 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 20 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 20 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 16 |
| Digoxin | Digoxin | 17 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 16 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | 12 |
| Cilostazol | Cilostazol | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Ofloxacin | Ofloxacin | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Nystatin | Nystatin | 12 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 11 | suppressed |
| Klor-Con 10 | Potassium Chloride | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $105.58 · 4 records | Medtronic, Inc. | BREZTRI, Dexcom G6 Transmitter, Kerendia, MINIMED 780G | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error